Pathogenesis of multiple sclerosis - Recent advances;Pathogenese der Multiplen Sklerose: Stand der Forschung

Wiener Medizinische Wochenschrift

Volumn 146, Issue 19-20, 1996, Pages 520-527

  Hartung, H P ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

multiple sclerosis; pathogenesis

Indexed keywords

AUTOANTIBODY; GAMMA INTERFERON; MYELIN ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AUTOIMMUNITY; CELL PROLIFERATION; DEMYELINATING NEUROPATHY; DISEASE COURSE; HUMAN; MACROPHAGE; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; PATHOGENESIS; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

AUTOANTIBODIES; BRAIN; HUMANS; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MULTIPLE SCLEROSIS; MYELIN PROTEINS; MYELIN SHEATH; OLIGODENDROGLIA; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029994223     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. Amor S, Groome N, Linington C. Morris MM, Dornmair K, Gardinier MV, Matthieu JM, Baker D: Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice. J Immunol 1994;153:4349-4356.
2. Archelos JJ, Jung S, Maurer M, Schmied M, Lassmann H, Tamatani T, Miyasaka M, Toyka KV, Hartung HP: Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular adhesion molecule ICAM-I Ann Neurol 1993;34:145-154.
3. Bagasara O, Michaels FH, Zheng YM, Bobroski LE, Spitsin SV, Fu ZF, Tawadros R, Koprowski H: Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proc Natl Acad Sci USA. 1995;92:12041-12045.
4. + T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis. J Clin Invest 1995;95:2711-2719.
5. Battistini L, Selmaj K, Kowal C, Ohmen J, Modlin RL, Raine CS, Brosnan CF: Multiple Sclerosis: Limited diversity of the V2-J3 T cell receptor in chronic active lesions. Ann Neurol 1995;37:198-203.
6. Bauer J, Wekerle H, Lassmann H: Apoptosis in brain-specific autoimmune disease. Curr Opin Immunol 1995;7:839-843.
7. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J: Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 1988;78:318-323.
8. Birnbaum G: Stress proteins: their role in the normal central nervous system and in disease states, especially multiple sclerosis. Springer Sem Immunopathol 1995;17:107-118.
9. Boullerne AI. Petry KG, Meynard M, Geffard M: Indirect evidence for nitric oxide involvement in multiple sclerosis by characterization of circulating antibodies directed against conjugated S-nitrosocysteine. J Neuroimmunol 1995;60:117-124.
10. Bö L, Dawson TM, Wesselingh S, Mork S, Choi S, Kong PA, Hanley D, Trapp BD: Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol 1994;36:778-786.
11. Brocke S, Veromaa T, Weissman IL, Gijbels K, Steinman L: Infection and multiple sclerosis: a possible role for superantigens? Trends Microbiol 1994;2:250-254.
12. Brosnan C, Raine CS: Mechanisms of immune injury in multiple sclerosis. Brain Pathol 1996;6:243-257.
13. Brosnan CF, Cannella B, Battistini L, Raine CS: Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology 1995;45:S16-S21.
14. Butcher EC, and Picker LJ: Lymphocyte homing and homeostasis. Science 1996;272:60-66.
15. Challoner PB, Smith KT, Parker JD. MacLeod DL. Coulter SN, Rose TM, Schultz ER, Bennett JL, Garber RL, Chang M, et al: Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad 1995;92:7440-7444.
16. Chia LS, Thompson JE, Moscarello MA: Disorder in human myelin induced by superoxide radical: an in vitro investigation. Biochem Biophys Res Commun 1983;117:141-146.
17. Chofflon M, Juillard C, Juillard P, Gauthier G, Grau GE: Tumor necrosis factor alpha production as a possible predictor of relapse in patients with multiple sclerosis. Eur Cytokine Netw 1992;3:523-531.
18. Compston DA, Morgan BP, Campbell AK, Wilkins P, Cole G, Thomas ND, Jasani B: Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol Appl Neurobiol 1989;15:307-316.
19. Compston DA, Scolding N,Noble M: Pathogenesis of demyelinating diseases: Insights form cell biology. Trends Neurosci 1991;14:175-182.
20. Cross A, Asher L, Seguin M, Yuan L, Kelly N, Hammack C, Sadoff J, Gemski P jr: The importance of a lipopolysaccharide-initiated. cytokine-mediated host defense mechanism in mice against extraintestinally invasive Escherichia coli. J Clin Invest 1995;96:676-686.
21. Cross AH, Misko TP, LIn RF, Hickey WF, Trotter JL, Tilton RG: Aminoguanidine, an inhibitor of inducible nitric oxide synthase. ameliorates experimental autoimmune encephalomyelitis in SJL mice: J Clin Invest 1994;93:2684-2690.
22. De Simone R, Giampaolo A, Giometto B, Gallo P, Levi G, Peschle C, Aloisi F: The costimulatory molecule B7 is expressed on human microglia in culture and in multiple sclerosis acute lesions. J Neuropathol Exp Neurol 1995;54:175-187.
23. Freedman MS, Ruijs TC, Selin LK, Antel JP: Peripheral blood gamma-delta T cells lyse fresh human brain-derived oligodendrocytes [see comments]. Ann Neurol 1991;30:794-800.
24. Gijbels K, Galardy RE, Steinman L: Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 1994;94:2177-2182.
25. Giovannoni G, Hartung H-P: The immunopathogenesis of multiple sclerosis and Guillain-Barré syndrome. Curr Opin Neurol 1996;9:165-177.
26. Gordon EJ, Myers KJ, Dougherty JP, Rosen H, Ron Y: Both anti-CD11a (LFA-I) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol 1995;62:153-160.
27. Hart N, Fabry Z: CNS antigen presentation. Trends Neurosci 1995;18:475-481.
28. Hartung H-P: Pathogenesis of inflammatory demyelination: implications for therapy. Curr Opin Neurol 1995;8:191-199.
29. Hartung HP, Jung S, Stoll G, Zielasek J, Schmidt B, Archelos JJ, Toyka KV: Inflammatory mediators in demyelinating disorders of the CNS and PNS. J Neuroimrnunol 1992;40:197-210.
30. Hartung H-P: Neurological progress: Immune-mediated demyelination. Ann Neurol 1993;33:563-567.
31. Hartung HP, Michels M, Reiners K, Seeldrayers P, Archelos JJ, Toyka KV: Soluble ICAM-1 serum levels in multiple sclerosis and viral encephalitis. Neurology 1993;43:2331-2335.
32. Hartung HP, Archelos JJ, Zielasek J, Gold R, Koltzenburg M, Reiners KH, Toyka KV: Circulating adhesion molecules and inflammatory mediators in demyelination: a review. Neurology 1995;45:S22-S32.
33. Hartung HP, Reiners K, Archelos JJ, Michels M, Seeldrayers P, Heidenreich F, Pflughaupt KW, Toyka KV: Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann Neurol 1995;38:186-193.
34. Hauser SL, Doolittle TH, Lincoln R, Brown RH, Dinarello CA: Cytokine accumulation in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology 1990;40:1735-1739.
35. Hofmann FM, Hinton DR, Johnson K, Merrill JE: Tumor necrosis factor identified in multiple sclerosis. J Exp Med 1989;170:607-612.
36. Hohlfeld R, Meinl E, Weber F, Zipp F, Schmidt S, Sotgiu S, Goebels N, Voltz R, Spuler S, Iglesias A, et al: The role of autoimmune T lymphocytes in the pathogenesis of multiple sclerosis. Neurology 1995;45:S33-S38.
37. Johns TG, Kerlero De Rosbo N, Menon KK, Abo S, Gonzales MF, Bernard CCA: Myelin oligodendrocyte glycoprotein induces a demyelinating encephalomyelitis resembling multiple sclerosis. J Immunol 1995;154:5536-5541.
38. Johnson AW, Land JM, Thompson EJ, Bolanos JP, Clark JB, Heales SJ: Evidence for increased nitric oxide production in multiple sclerosis [letter]. J Neurol Neurosurg. Psychiatry 1995;58:107.
39. Kent SJ, Karlik SJ, Cannon C, Hines DK, Yednock TA, Fritz LC, Horner HC: A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelltis. J Neuroimmunol 1995;58:1-10.
40. Kerlero De Rosbo N, Milo R, Lees MB, Burger D, Bernard CCA, Ben-Nun A: Reactivity to myelin antigens in multiple sclerosis. J Clin Invest 1993;92:2602-2608.
41. Kerlero De Rosbo N, Mendel I. Ben Nun A: Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical clinical course, induced in PL/J mice by myelin oligodendrocyte glycoprotein (MOG)-derived peptide: preliminary analysis of MOG T cell epitopes. Eur J Immunol 1995;25:985-993.
42. Kirschning E, Rutter G, Uhlig H, Derniek R: A sulfatide-reactive human monoclonal antibody obtained from a multiple sclerosis patient selectively binds to the surface of oligodendrocytes. J Neuroimmunol 1995;56:191-200.
43. Koh DR, Fung Leung WP, Ho A, Gray D, Acha Orbea H, Mak TW: Less mortality but more relapses in experimental allergic encephalomyelitis in CD8-/- mice. Science 1992:256:1210-1213.
44. Konat GW, Offner H: Density distribution of myelin fragments isolated from control and multiple sclerosis brain. Neurochem Int 1983;4:241-246.
45. Konat GW, Wiggins RC: Effect of reactive oxygen species on myelin membrane proteins. J Neurochem 1985:45:1113-1118.
46. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, Weiner HL, Nabavi N, Gilmcher LH: B7-1 and B7-2 costimulatory molecules activate differentially the Th1 /Th2 developmental pathways: Application to autoimmune disease therapy. Cell 1995;80:707-718.
47. Lehmann PV, Sercarz EE, Forsthuber T, Dayan CM, Gammon G: Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol Today 1993;14:203-208.
48. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL: T cell geltinases mediate basement membrane transmigration in vitro. J Immunol 1995;154:4379-4389.
49. Li F, Linan MJ, Stein MC, Faustman DL: Reduced expression of peptide-loaded HLA class I molecules on multiple sclerosis lymphocytes [see comments]. Ann Neurol 1995;38:147-154.
50. Linington C, Bradl M, Lassmann H, Brunner C, Vass K: Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 1988;130:443-454.
51. Link J, Söderström M, Olsson T, Bo H, Ljungdahl A, Link H: Increased transforming growth factor-b, interleukin-4, and interferon-t in multiple sclerosis. Ann Neurol 1994;36:379-386.
52. Lucchinetti CF, Brück W, Rodriguez M, Lassmann H: Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 1996;6:259-274.
53. Markovic Plese S, Fukaura H, Zhang J, al Sabbagh A, Southwood S, Sette A, Kuchroo VK, Hafler DA: T cell recognition of immunodominant and cryptic proteolipid protein cpitopes in humans. J Immunol 1995;155:982-992.
54. Martin R, McFarland HF: Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit Rev Clin Lab Sci 1995;32:121-182.
55. 2+ influx in patients with relapsing-remitting multiple sclerosis. Neurology 1996;46:1416-1421.
56. Matsuda M, Tsukada N, Miyagi K, Yanagisawa N: Increased levels of soluble tumor necrosis factor receptor in patients with multiple sclerosis and HTLV-1-associated myelopathy. J Neuroimmunol 1994;52:33-40.
57. b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells. Eur J Immunol 1995;25:1951-1959.
58. Merrill JE, Ignarro LJ, Sherman MP, Melinek J, Lane TE: Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J Immunol 1993;151:2132-2141.
59. Miller SD, McRae BL, Vanderlugt CL, Nikcevich KM, Pope JG, Pope L, Karpus WJ: Evolution of the T-cell repertoire during the course of experimental immune-mediated demyelinating diseases. Immunol Rev 1995;144:225-244.
60. Moreau T, Coles A, Wing M, Isaacs J, Hale G, Waldmann H, Compston A: Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996;119:225-237.
61. Morgan BP: Physiology and pathophysiology of complement: Progress and trends. Crit Rev Clin Lab Sci 1995;32:265-298.
62. Navikas V, He B, Link J, Haglund M, Söderström M, Frcdrikson S, Ljungdahl A, Höjeberg B, Qiao J, Olsson T, et al: Augmented expression of tumour necrosis factor-alpha and lymphotoxin in mononuclear cells in multiple sclerosis and optic neuritis. Brain 1996;119:213-223.
63. Neumann H, Cavalie A, Jenne DE, Wckerle H: Induction of MHC class I genes in neurons. Science 1995;269:549-552.
64. Olsson T, Baig S, Höjeberg B, Link H: Antimyelin basic protein and antimyelin antibody producing cells in multiple sclerosis. Ann Neurol 1990;27:132-136.
65. Olsson T, Wang W-Z, Höjeberg B, Kostulas V, Jiang Y-P, Anderson G, Ekre H-P, Link H: Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-t. J Clin Invest 1990;86:981-985.
66. Olsson T: Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev 1995;144:245-268.
67. Panitch HS, Hirsch RL, Schindler J, Johnson KP: Treatment of multiple sclerosis with gamma interferon: exacerbation associated with activation of the immune system. Neurology 1987;37:1097-1102.
68. Parkinson JF, Mitrovic B, Merrill JE: The role of nitric oxide in multiple sclerosis. J Molec Med 1996 (in press).
69. Pender MP, McCombe PA, Yoong G, Nguyen KB: Apoptosis of alpha beta T lymphocytes in the nervous system in experimental autoimmune encephalomyelitis: its possible implications for recovery and acquired tolerance. J Autoimmun 1992;5:401-410.
70. Piddlesden SJ, Storch MK, Hibbs M, Freeman AM, Lassmann H, Morgan BP: Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J Immunol 1994;152:5477-5484.
71. Racke MK, Scott DE, Quigley L, Gray GS, Abe R, June CH, Perrin PJ: Distinct roles for B7-1 (CD80) and B7-2 (CD86) in the initiation of experimental allergic encephalomyelitis. J Clin Invest 1995;96:2195-2203.
72. Raine CS, The Dale E, McFarlin Memorial Lecture: The immunology of the multiple sclerosis lesion. Ann Neurol 1994;36 (suppl): S61-S72.
73. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, Lüer W, Poser S: Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology 1994;44:1523-1526.
74. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, Luer W, Helwig A, Poser S: Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995;37:82-88.
75. Rosenberg GA, Dencoff JE, Correa N, Reiners M, Ford CC: Effect of steroids on CSF matrix metalloproteinases in multiple scelerosis: Relation to blood-brain barrier injury. Neurology 1996;46:1626-1632.
76. Rosengren LE, Lycke J, Andersen O: Glial fibrillary acidic protein in CSF of multiple sclerosis patients: Relation to neurological deficit. J Neurol Sci 1995;133:61-65.
77. Ruddle NH, Bergman CM, McGrath KM, Lingenheld EG, Grunnet ML, Padula SJ, Clark RB: An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 1990;172:1193-1200.
78. Ruuls S, van der Linden S, Huitinga I, Dijkstra CD: Aggravation of experimental allergic encephalomyelitis by administration of nitric oxide synthase inhibitors. Clin Exp Immunol 1996;103:467-474.
79. Sanders ME, Koski CL, Robbins D, Shin ML, Frank MM, Joiner KA: Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis. J Immunol 1986;136:4456-4459.
80. Schmied M, Breitschopf H, Gold R, Zischler H, Rothe G, Wekerle H, Lassmann H: Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis. Evidence for programmed cell death as a mechanism to control inflammation in the brain. Am J Pathol 1993;143:446-452.
81. Selmaj K, Raine CS: Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988;23:339-346.
82. Selmaj K, Brosnan CF, Raine CS: Colocalization of lymphocytes bearing gamma delta T-cell receptor and heat shock protein hsp65+ oligodendrocytes in multiple sclerosis. Proc Natl Acad Sci USA 1991;88:6452-6456.
83. Selmaj K, Raine CS, Cross AH: Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 1991;30:694-700.
84. Selmaj K, Raine CS, Farooq M, Norton WT, Brosnan CF: Cytokine cytotoxicity against oligodendrocytes: apoptosis induced by lymphotoxin. J Immunol 1991;147:1522-1529.
85. Sharief MK, Hentges R: Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis [see comments]. N Engl J Med 1991;325:467-472.
86. Sharief MK, Noori MA, Ciardi M, et al: Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis: correlation with TNF-α and blood-brain barrier damage. J Neuroimmunol 1993;43:15-22.
87. Shimonkevitz R, Colburn C, Burnham JA, Murray RS, Kotzin BL: Clonal expansions of activated gamma/delta T cells in recent-onset multiple sclerosis. Proc Natl Acad Sci USA 1993;90:923-927.
88. Sippy BD, Hofman FM, Wallach D, Hinton DR: Increased expression of tumor necrosis factor-alpha receptors in the brains of patients with AIDS. J Acqu Imm Def Syndr Hum Retrovirol 1995;10:511-521.
89. Söderström M, Hillert J, Link J, Navikas V, Fredrikson S, Link H: Expression of IFN-gamma, IL-4 and TGF-beta in multiple sclerosis in relation to HLA-Dw2 phenotype and stage of disease. Multiple Sclerosis 1995;1:173-180.
90. Steinman L, Waisman A, Altmann D: Major T-cell responses in multiple sclerosis. Mol Med Today 1995;1:79-83.
91. Stinissen P, Vandevyver C, Medaer R, Vandegaer L, Nies J, Tuyls L, Hafler DA, Raus J, Zhang J: Increased frequency of gamma delta T cells in cerebrospinal fluid and peripheral blood of patients with multiple sclerosis. Reactivity, cytotoxicity, and T cell receptor V gene rearrangements. J Immunol 1995;154:4883-4894.
92. Stüve O, Dooley NP, Uhm JH, Antel JP, Francis GS, Williams G, Yong VW: Interferon beta 1-b decreases the migration of T lymphocytes in vitro: Effects on matix metalloproteinase-9. Ann Neurol 1996 (in press).
93. Sun J, Link H, OlssonT, Xiao BG, Andersson G, Ekre HP, Linington C, Diener P: T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis. J Immunol 1991;146:1490-1495.
94. Sun JB, Olsson T, Wang WZ, Xiao BG, Kostulas V, Fredrikson S, Ekre HP, Link H: Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur J Immunol 1991;21:1461-1468.
95. Swanborg RH: Animal models of human disease: Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease. Clin Immunol Immunopathol 1995;77:4-13.
96. Tchélingérian JL, Monge M, Le Saux F, Zalc B, Jacque C: Differential oligodendroglial expression of the tumor necrosis factor receptors in vivo and in vitro. J Neurochem 1995;65:2377-2380.
97. Theofilopoulos AN: The basis of autoimmunity. Part I. Mechanisms of aberrant self-recognition. Immunol Today 1995;16:90-98.
98. Thompson AJ, Kermode AG, Wicks D, MacManus DG, Kendall BE, Kingsley PED, McDonald WI: Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62.
99. Tracey KJ, Cerami A: Tumor necrosis factor: an updated review of its biology. Crit Care Med 1993;21:S415-S422.
100. Trotter JL, Collins KG, van der Veen RC: Serum cytokine levels in chronic progressive multiple sclerosis: interleukin-2 levels parallel tumor necrosis factor-alpha levels. J Neuroimmunol 1991;33:29-36.
101. van Noort JM, van Sechel AC, Bajramovic JJ, El Ouagmiri M, Polman CH, Lassmann H, Ravid R: The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis. Nature 1995;375:798-801.
102. Warren KG, Catz I: Relative frequency of autoantibodies to myelin basic protein and proteolipid protein in optic neuritis and multiple sclerosis cerebrospinal fluid. J Neurol Sci 1994;121:66-73.
103. Warren KG, Catz I, Johnson E, Mielke B: Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis. Ann Neurol 1994;35:280-289.
104. Wekerle H, Kojima K, Lannes Vieira J, Lassmann H, Linington C: Animal models. Ann Neurol 1994:36 (suppl): S47-S53.
105. Windhagen A, Newcombe J, Dangond F, Strand C, Woodroofe MN, Cuzner ML, Hafler DA: Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 1995;182:1985-1996.
106. Wucherpfennig KW, Newcombe J, Li H, Keddy C, Cuzner ML, Hafler DA: Gamma delta T-cell receptor repertoire in acute multiple sclerosis lesions. Proc Natl Acad Sci USA 1992;89:4588-4592.
107. Wucherpfennig KW, Zhang J, Witek C, Matsui M, Modabber Y, Ota K, Hafler DA: Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. J Immunol 1994;152:5581-5592.
108. Wucherpfennig KW, Hafler DA: A review of T-cell receptors in multiple sclerosis: clonal expansion and persistence of human T-cells specific for an immunodominant myelin basic protein peptide. Ann N Y Acad Sci 1995;756:241-258.
109. Wucherpfennig K, Hafler DA, Strominger JL: Structure of human T cell receptors specific for an immunodominant myelin basic protein peptide: Positioning of T cell receptors on HLA-DR2/peptide complexes. Proc Natl Acad Sci 1995;92:8896-8900.
110. Wucherpfennig KW, Strominger JL: Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995;80:695-705.
111. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Nathan K: Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature 1992;356:63-66.
112. Zielasek J, Tausch M, Toyka KV, Hartung HP: Production of nitrite by neonatal rat microglial cells/brain macrophages. Cell Immunol 1992;141:111-120.
113. Zielasek J, Jung S, Gold R, Liew FY, Toyka KV, Hartung HP: Administration of nitric oxide synthase inhibitors in experimental autoimmune neuritis and experimental autoimmune encephalomyelitis. J Neuroimmunol 1995;58:81-88.
114. + T cells. Ann Neurol 1995:38:723-730.